Effect of Sitagliptin on Micro150-5p in patients with T2DM with left ventricular diastolic dysfunction
Abstract
OBJECTIVE: Aim: To clarify Sitagliptin effect on left ventricular diastolic dysfunction in T2DM, to investigate the potential effect of Sitagliptin on epigenetic modulation (Micro RNA150-5P) and inflammatory process.
PATIENTS AND METHODS: Materials and Methods: This study was carried out at a single center and is cross-sectional, descriptive, and observational. A specialist cardiologist selected a cohort of sixty individuals who had both left ventricular diastolic failure and type 2 diabetes mellitus (T2DM). The study was carried out at AL-Diwaniyah teaching hospital and the department of pharmacology and therapeutics, school of medicine, university of Al-Qadisiyah, Iraq. Total RNA was isolated using Trizol reagent (Genaid, Korea) and the concentration of RNA was determined. The primer amplification was performed according to the instructions published by AddBio (Korea) for the AddScript RT-qPCR Syber master kit. Transthoracic echocardiography measuring were patients at rest utilizing a commercially accessible ultrasound machine (Vinno E20; Echo Ultrasound AS, china). Ultrasound imaging acquisitions were automatically saved from at least three following cardiac contractions for subsequent processing. Standard parameters (LVED, LVES, and LVEF) were acquired as previously explained.
RESULTS: Results: Our results indicate a significant down regulation of miR-150-5p in the Sitagliptin treated group (P<0.0001) in comparison with metformin treatment. This was analyzed by Graph pad…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.